On October 26, 2026, the FDA approved talazoparib (Talzenna, Pfizer) with enzalutamide (Xtandi) for adults with HRR gene-mutated metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer, based on the Phase 3 TALAPRO-3 trial: rPFS HR 0.48 (95% CI 0.36-0.65), median not reached vs 45.8 months; OS immature. The mCRPC approval (TALAPRO-2, 2023) is separate.
FDA Approval: Talazoparib + Enzalutamide in HRR Gene-Mutated mAPMN/S Prostate Cancer
FDA APPROVEDOctober 26, 2026
“On October 26, 2026, the Food and Drug Administration (FDA) approved talazoparib (Talzenna, Pfizer Inc.) in combination with enzalutamide for the treatment of adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer with homologous recombination repair (HRR) gene mutations, as detected by an FDA-authorized test.” (FDA)
Companion diagnostics: FoundationOne CDx (tumor tissue) and FoundationOne Liquid CDx (blood), previously approved by the FDA to identify patients with prostate cancer with HRR gene alterations for this combination. (FDA)
HRR genes tested in TALAPRO-3: ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, RAD51C, by tumor tissue or ctDNA-based next-generation sequencing. (FDA)
Efficacy in the FDA notice: 599 patients randomized 1:1 to enzalutamide plus talazoparib or placebo, with continuous ADT. Investigator-assessed rPFS (RECIST v1.1 and PCWG3 for bone): median not reached (95% CI NR-NR) vs 45.8 months (95% CI 37.7-NR); HR 0.48 (95% CI 0.36-0.65); p<0.0001. OS data were immature at the time of the rPFS analysis. (FDA)
Same analysis, as presented and published: rPFS HR 0.481 (95% CI 0.357-0.647); interim OS HR 0.767 (95% CI 0.564-1.044), P=0.0905, not statistically significant. (NEJM / ASCO 2026 LBA5007; data cutoff Feb 18, 2026)
Dosage: talazoparib 0.5 mg orally once daily with enzalutamide until disease progression or unacceptable toxicity; patients should also receive a GnRH analog or have had a bilateral orchiectomy. (FDA)
Warnings and precautions: myelodysplastic syndrome/acute myeloid leukemia, myelosuppression, and embryo-fetal toxicity. (FDA)
Review: priority review; Project Orbis with Australia’s TGA and Health Canada, where reviews are ongoing. (FDA)
Talazoparib plus enzalutamide has been FDA approved since June 2023 for adults with HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC), based on TALAPRO-2. The October 26, 2026 approval, based on TALAPRO-3 (which enrolled patients with metastatic castration-sensitive prostate cancer), covers HRR gene-mutated metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer. The two indications rest on different trials and different patient populations.
rPFS (primary) — MET — HR 0.481 (95% CI 0.357-0.647); median rPFS not reached; 3-year rPFS 76.6%. (ASCO 2026 LBA5007 slide; data cutoff Feb 18, 2026)
Time to PSA progression — 3-year PSA-progression-free 78.3% vs 62.7%; HR 0.513; p<0.0001. (ASCO 2026 LBA5007 slide; data cutoff Feb 18, 2026)
Overall survival — Interim, not statistically significant (immature): 3-year OS 77.8% vs 71.6%; HR 0.767 (95% CI 0.564-1.044; p=0.0905). (ASCO 2026 LBA5007 slide; data cutoff Feb 18, 2026)
Patient-reported outcomes — No clinically meaningful between-arm differences (≥5-point threshold) in GHS/QoL, functioning or symptom scales except appetite loss (worse with TALA + ENZA; difference 5.2, 95% CI 2.5-8.0); time to deterioration in GHS/QoL, urinary symptoms and worst pain comparable. (ESMO 2026 abstract 2222RO; data cutoff Feb 18, 2026)
Regulatory — FDA APPROVED October 26, 2026 for adults with HRR gene-mutated metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer, as detected by an FDA-authorized test (FoundationOne CDx / FoundationOne Liquid CDx). Separate from the June 2023 mCRPC approval (TALAPRO-2). (FDA)
Compiled and reviewed by the KOL Pulse research team, led by Brian Shields, Founder, KOL Pulse. Last updated October 26, 2026.
Physician Reactions · Newest First
TALAPRO-3: FDA Approval and ESMO 2026 Reactions
Physician posts from approval day and from the TALAPRO-3 safety, patient-reported outcome, PSA and ctDNA analyses at ESMO 2026, plus earlier meeting commentary. Topics under debate: who should get HRR testing and when, BRCA vs non-BRCA benefit, anemia and dose reductions, quality of life, and how the castration-sensitive data sit next to TALAPRO-2 in mCRPC.
Detailed Data from ASCO 2026 LBA5007 · Simultaneous NEJM Publication (May 30, 2026)
TALAPRO-3 builds on the topline results Pfizer announced in March 2026. Today's late-breaking oral presentation at ASCO 2026 (Abstract LBA5007, presented by Neeraj Agarwal, MD FASCO, Huntsman Cancer Institute, University of Utah) delivered the detailed dataset — including subgroup analyses, safety, and patient-reported outcomes — with concurrent publication in the New England Journal of Medicine.
Distinct from TALAPRO-2. TALAPRO-2 was the talazoparib + enzalutamide mCRPC study that received FDA approval in June 2023 for HRR gene-mutated mCRPC. TALAPRO-3, the basis of the October 26, 2026 FDA approval, moves the regimen earlier in the disease course — into first-line metastatic castration-SENSITIVE prostate cancer (mCSPC / mHSPC) with HRR alterations.
Influence Leaders
Top KOLs Discussing TALAPRO-3
Neeraj Agarwal, MD, FASCO
@neerajaiims
Presenter · ASCO 2026 LBA5007
Karine Tawagi MD
@drkarinetawagi
4.2K impressions
Toni Choueiri, MD
@drchoueiri
4.1K impressions
Roberto Iacovelli
@DrIacovelli
3.7K impressions
Katy Beckermann
@katy_beckermann
2.5K impressions
Shilpa Gupta
@shilpaonc
1.4K impressions
Yüksel Ürün
@DrYukselUrun
1.4K impressions
Sumanta K. Pal, MD, FASCO
@montypal
836 impressions
Tom Powles
@tompowles1
645 impressions
Conference Presentations
TALAPRO-3 Key Slides & Visuals
ESMO 2026 analyses first, then trial slides and infographics shared by KOLs around the ASCO 2026 late-breaking oral presentation (Neeraj Agarwal, Huntsman Cancer Institute, May 30 2026). Click any image to expand.
ESMO 2026 · Madrid · TALAPRO-3 PRO, PSA and ctDNA analyses (exploratory) · newest first
Time to (definitive) deterioration — TALA + ENZA (n=240) vs PBO + ENZA (n=234)
Measure
Events, TALA + ENZA
Events, PBO + ENZA
Median (95% CI), mo, TALA + ENZA
Median (95% CI), mo, PBO + ENZA
Stratified HR (95% CI)
GHS/QoL (EORTC QLQ-C30), definitive
92/240
78/234
38.0 (35.1–46.0)
46.0 (37.8–49.9)
1.16 (0.85–1.58)
Urinary symptoms (EORTC QLQ-PR25), definitive
42/240
46/234
NR (48.8–NR)
51.4 (48.8–NR)
0.94 (0.61–1.44)
Worst pain (BPI-SF)
81/240
93/234
NR (32.9–NR)
NR (23.0–NR)
0.82 (0.61–1.11)
ESMO 2026 TALAPRO-3 PRO analysis; data cutoff February 18, 2026 (per the PRO design slide). Exploratory; HRs are nominal (not alpha-controlled), per the design slide.
[Baseline demographics and treatment duration (PRO population)*] TALA + ENZA (n=240) | PBO + ENZA (n=234)
Median age (IQR), years: 70 (63-76) | 68.5 (63-75)
Race, n (%): White 123 (51) | 128 (55); Black or African American 4 (2) | 2 (1); Asian 103 (43) | 98 (42); American Indian or Alaska Native 4 (2) | 2 (1); Not reported 6 (2) | 4 (2)
Geographical region, n (%): Asia 101 (42) | 98 (42); Europe 91 (38) | 100 (43); North America 34 (14) | 24 (10); Rest of the world 14 (6) | 12 (5)
Median treatment duration, months: Talazoparib/placebo 35.0 | 34.1; Enzalutamide 35.9 | 34.0
Baseline PRO completion rates, TALA + ENZA | PBO + ENZA: EORTC QLQ-C30 68% | 66%; EORTC QLQ-PR25 66% | 66%; BPI-SF 80% | 79%; EQ-5D-5L 65% | 65%
[Comparable mean change from baseline in GHS/QoL per EORTC QLQ-C30] Score range 0-100. Estimated overall mean change from baseline difference (95% CI): -3.7 (-6.5 to -1.0)*
Number evaluable (weeks 5 to 213): TALA + ENZA 183, 173, 171, 173, 164, 172, 166, 161, 154, 148, 144, 136, 131, 129, 120, 117, 113, 103, 75, 50, 34, 18, 9; PBO + ENZA 169, 164, 170, 167, 162, 168, 156, 153, 151, 146, 139, 134, 126, 117, 109, 106, 99, 87, 60, 39, 29, 20, 10
[EORTC QLQ-C30 symptom scale; slide heading cropped in this photo, identified as appetite loss in Dr. Klaassen's post; higher = worsened] Estimated overall mean change from baseline difference (95% CI): 5.2 (2.5-8.0)*. Number evaluable as above.
[TALAPRO-3 trial design: PRO analysis] Key eligibility: HRRm mCSPC; metastatic disease confirmed by positive bone scan or metastatic lesion by CT or MRI scan; ECOG PS 0 or 1; ongoing ADT; <=3 months of prior ADT with/without ARPI for mCSPC; prior docetaxel not permitted. Talazoparib 0.5 mg + enzalutamide 160 mg QD vs placebo + enzalutamide 160 mg QD, 1:1, N=599. Stratification: de novo vs relapsed mCSPC; high- vs low-volume disease; BRCAm vs non-BRCAm.
Primary endpoint: rPFS by investigator assessment. Key secondary endpoint: OS (alpha-protected). PRO endpoints: change from baseline in GHS/QoL and symptoms; TTDD in GHS/QoL; TTDD in EORTC QLQ-PR25; TTD in BPI-SF. PRO instruments: EORTC QLQ-C30 (cancer specific); EORTC QLQ-PR25 (prostate cancer-specific); BPI-SF (pain); EQ-5D-5L (general health status). Assessed at baseline, every 4W to W25, then every 8W to W57, then every 12W up to the safety follow-up visit. A >=5-point difference between groups for deterioration in EORTC-QLQ measures was considered clinically meaningful. Data cutoff: February 18, 2026.
HRRm gene panel: ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, RAD51C.
[Comparable mean change from baseline in physical functioning per EORTC QLQ-C30] Estimated overall mean change from baseline difference (95% CI): -2.5 (-5.1 to 0.1)*
[Similar mean change from baseline between arms in fatigue per EORTC QLQ-C30] Estimated overall mean change from baseline difference (95% CI): 3.2 (0.2-6.2)*
Differences in estimated overall mean scores between arms were assessed by longitudinal mixed-effects model for repeated measures.
rPFS by baseline ctDNA status (ITT excluding patients in China)
Group
n
Events
Median rPFS, mo (95% CI)
A. TALA + ENZA ctDNA+ at BL
83
24
NR (NR–NR)
B. TALA + ENZA ctDNA− at BL
147
32
NR (NR–NR)
C. PBO + ENZA ctDNA+ at BL
75
40
26.7 (18.2–NR)
D. PBO + ENZA ctDNA− at BL
149
50
NR (45.8–NR)
Unstratified HR: A vs B 1.59 (0.94–2.70), p=0.08; A vs C 0.47 (0.28–0.78), p=0.003; B vs D 0.62 (0.39–0.96), p=0.03; C vs D 2.15 (1.42–3.26), p=0.0002. Data cutoff February 18, 2026; rPFS by investigator assessment. Survival-curve numbers transcribed from the slide (RULE 23 table); medians and HRs only as printed.
rPFS by ctDNA status at baseline and week 5, TALA + ENZA arm
Group
n
Events
Median rPFS, mo (95% CI)
A. ctDNA+ at BL and Wk 5
12
6
17.3 (9.1–NR)
B. ctDNA+ at BL, ctDNA− at Wk 5
55
14
NR (NR–NR)
C. ctDNA− at BL and Wk 5
114
25
NR (NR–NR)
D. ctDNA− at BL, ctDNA+ at Wk 5
4
3
14.3 (5.6–NR)
Unstratified HR: B vs A 0.36 (0.14–0.93), p=0.03; C vs A 0.23 (0.09–0.56), p=0.0004; C vs B 0.72 (0.38–1.39), p=0.33. Data cutoff February 18, 2026; rPFS by investigator assessment. Survival-curve numbers transcribed from the slide (RULE 23 table); medians and HRs only as printed.
[Conclusions] In TALAPRO-3, baseline and on-treatment Week 5 ctDNA tumor fraction showed potential prognostic utility for rPFS in mCSPC. Conversion of ctDNA tumor fraction from positive at baseline to negative at Week 5, which was higher with TALA + ENZA compared with PBO + ENZA, correlated with improved rPFS. Further investigation will look at whether ctDNA provides independent prognostic value beyond established markers (e.g., PSA at 6 months) through multivariate analysis.
ctDNA tumor fraction has potential as a prognostic biomarker and may improve risk stratification and therapeutic monitoring in patients with mCSPC.
(Survival-curve slides in this post are captured in the tables above. Population: ITT excluding patients in China; rPFS by investigator assessment; data cutoff February 18, 2026.)
rPFS by ctDNA status at baseline and week 5, PBO + ENZA arm
Group
n
Events
Median rPFS, mo (95% CI)
A. ctDNA+ at BL and Wk 5
21
14
11.5 (3.6–29.3)
B. ctDNA+ at BL, ctDNA− at Wk 5
45
23
35.1 (18.4–NR)
C. ctDNA− at BL and Wk 5
121
39
NR (46.0–NR)
D. ctDNA− at BL, ctDNA+ at Wk 5
2
2
4.7 (3.9–NR)
Unstratified HR: B vs A 0.43 (0.22–0.83), p=0.01; C vs A 0.23 (0.12–0.43), p<0.0001; C vs B 0.55 (0.33–0.92), p=0.02. Shown because no physician-shared copy of these two slides exists. Data cutoff February 18, 2026; rPFS by investigator assessment. Survival-curve numbers transcribed from the slide (RULE 23 table); medians and HRs only as printed.
[ctDNA+ to ctDNA- Conversion Rates Were Higher With TALA + ENZA]
ctDNA+ at baseline*: TALA + ENZA 67/269 (24.9%); PBO + ENZA 66/262 (25.2%)
Conversion to ctDNA- at Week 5, n (%): TALA + ENZA Yes 55 (82.1%) [95% CI, 70.4-90.0], No 12 (17.9%); PBO + ENZA Yes 45 (68.2%) [95% CI, 55.4-78.8], No 21 (31.8%)
ctDNA- at baseline*: TALA + ENZA 118/269 (43.9%); PBO + ENZA 123/262 (46.9%)
Conversion to ctDNA+ at Week 5, n (%): TALA + ENZA No 114 (96.6%) [95% CI, 91.0-98.9], Yes 4 (3.4%); PBO + ENZA No 121 (98.4%) [95% CI, 93.7-99.7], Yes 2 (1.6%)
(PBO + ENZA arm survival curve captured in the table above.)
ASCO®
"In the long term, this [combination
therapy] strategy could help address a
critical gap in care by ensuring that
more patients receive the benefits of
PARP inhibition for mCSPC rather than
relying on later lines of therapy that
many patients may never reach."
Neeraj Agarwal, MD, FASCO
Huntsman Cancer Institute
2026
ASCO
ANNUAL MEETING
TALAPRO-3: Trial Design
Primary endpoint
Key eligibility criteria
rPFS by investigator assessment
HRR gene-altered mCSPC
Key secondary endpoint
Metastatic disease confirmed by positive
bone scan or metastatic lesion by CT or
TALA 0.5 mg*
ENZA 160 mg QD
OS (alpha-protected)
MRI scan
Other secondary endpoints
ECOG PS 0 or 1
ORR per RECIST v1.1
Ongoing ADT
Duration of soft tissue response
1:1
N=599
PSA response
<3 months of prior ADT with/without ARPI
for mCSPC
Time to PSA progression
Time to subsequent
Prior docetaxel for mCSPC not permitted
PBO + ENZA 160 mg QD
antineoplastic therapy
Stratification factors
Time to first SSE
De novo vs relapsed mCSPC
Safety
Data cutoff: February 18, 2026
PROs
High- vs ow-volume disease
Exploratory endpoint
BRCAm vs non-BRCAm
PFS2
HRRm: ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, RAD51C
*0 mg CD the patient has побегия renal payment As per the DROSOCIA amendment Suptember 2021) CiricalTrass gov dentiller CT04925622 EAR lesting using and Foundation kguid
CDa) REARRERCA remputed omography EGOG Cospetative Osralogy Group performance states, gene allerations; Milimagretic resonance magna response cale, OS-overal
vavivit PT S2-teme to second programment or dealh PRO-paters reported ostcomo, PSA entigent, daily RECIST VI 1-Response valuation China 0. Solid Tumors version event
2026 ASCO
#ASCO26
- SENTED BY - Agenes
ASCO
I
ANNUAL MEETING
Preservation property whe - ASCO - voiced " - - -
KNOWLE 1004 CONDUERS CANCER
A-L
2026ASCO
ANNUAL MEETING
ASCO
ASCO
ASCO
ASCO
AS
SCO
AS
Key Takeaways
2
TALAPRO-3 met its primary endpoint: Treatment with talazoparib plus
enzalutamide (TALA + ENZA) prolonged rPFS (HR, 0.48) VS the ENZA
control arm in mCSPC with HRR gene alterations
The most common adverse events observed were hematologic (anemia,
decreased neutrophil count) and fatigue
These results support the use of TALA + ENZA as a potential treatment
option for patients with HRR gene-altered mCSPC
PRE SENTED BY: Neeraj Agarwal
ASCO
AMERICAN
CLINICAL OMCOLOGY
2026 ASCO
#ASCO26
KNOWLEDGE CONQUERS CANCE
ANNUAL MEETING
Presentation is property of the author and ASCO Permission required for reuse, contact permissions@asco org
18
Most Common (≥15%) All-Cause TEAEs
TALA ENZA
PBO + ENZA
(n=299)
(n=295)
Anemia
71
51
20
19
3
22
Adverse events of special interest
Fatigue
28
3
25
15
0.3 15
Neutrophil count decreased
27
11
16
4
5
3 patients with MDS in the TALA + ENZA
Neutropenia
22
9
13
2
3
arm (vs 1 in the PBO + ENZA arm) and 2
with AML (vs 0)
Asthenia
21
6
15
12
13
White blood cell count decreased
21
6
15
4
0.3 4
Venous embolic and thrombotic events
Hot flush
20
0
20
23
0
23
occurred in 7 patients in the TALA +
ENZA arm (vs 5 in the PBO + ENZA arm)
Decreased appetite
20
2
18
9
1 10
Back pain
19
1
18
19
1 20
Constipation
18
0
18
12
0.3 12
Nausea
17
0
17
8
0 8
Platelet count decreased
16
5
11
3033
Arthralgia
15
0
15
22
1 23
Fall
All grades
13
0.3 13
15
1 16
All grades
COVID-19
Grade 1 or 2
13 0.3 13
15
0 15
Grade 1 or 2
Hypertension
Grade 3 or 4
12
4
8
17
5
22
Grade 3 or 4
80
60
40
20
0
0
20
40
60
80
Data cutoff. February 18, 2026 (Safety population). Includes AEs occurring from the time of the first dose of study treatment through 28 days after the last dose of study treatment or before initiation of new systemic antineoplastic therapy,
excluding ADT, whichever occurs first. TEAEs were graded according to NCI CTCAE v4.03.
AESI=AE of special interest; AML acute myeloid leukemia; MDS=myelodysplastic syndrome; NCI CTCAE v4. 03=National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03.
2026 ASCO
PRESENTED BY: Neeraj Agarwal
ASCO
AMERICAN SOCIETY OF
#ASCO26
CLINICAL CHCOLOGY
ANNUAL MEETING
Presentation is property of the author and ASCO Permission required for reuse contact permissions@asco.org
KNOWLEDGE CONQUERS CANCER
TALAPRO-3: Trial Design
Primary endpoint
Key eligibility criteria
rPFS by investigator assessment
HRR gene-altered mCSPC
Key secondary endpoint
Metastatic disease confirmed by positive
OS (alpha-protected)
bone scan or metastatic lesion by CT or
TALA 0.5 mg*
ENZA 160 mg QD
Other secondary endpoints
MRI scan
ORR per RECIST v1.1
ECOG PS 0 or 1
Duration of soft tissue response
Ongoing ADT
1:1
N=599
PSA response
33 months of prior ADT with/without ARPI
Time to PSA progression
for mCSPC
Time to subsequent
Prior docetaxel for mCSPC not permitted
PBO
+ ENZA 160 mg QD
antineoplastic therapy
Time to first SSE
Stratification factors
Safety
De novo vs relapsed mCSPC
Data cutoff: February 18, 2026
PROs
High- vs low-volume disease
Exploratory endpoint
BRCAm vs non-BRCAm
PFS2
HRRm ATM, ATR. BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, RAD51C
CEME 5.B. 1 - - - - bes - - shopsery - 1000 per the - - environment Compensive / Oberagy 2021) Group - NC104821022 - - - Foundations and - real
performance
I
- n - X - - CO- dary REGIST as - - - has - majing, - 11 SSE - - - - -
I
magning
|
/
2026 ASCO
#ASCO26
- BURDED " - -
ANNUAL MILLERING
Personal
-
ASCO
-
I
CARRIER
Friday, May 29
2:15-5:45PM - GU Oral Abstracts - RCC +
Bladder
-A phase 2 randomized trial of radium-223
dichloride and cabozantinib in patients (pts) with
renal cell carcinoma (RCC) with bone metastases
(BM) - dr. Rana McKay
-A prospective, multi-center, phase 1b/II 1L
cadonilimab + axitinib in non-clear-cell RCC - Dr. Xu
Hu
-ctDNA analysis in KN-564 - Dr. Toni Choueiri
-Is the Best Yet to Come in Kidney Cancer? Dr.
Martin Voss
-Intravesical recombinant BCG combined with
chemo-immunotherapy (chemo-IO) as perioperative
therapy for patients with MIBC - Dr. Richard
Cathomas
-HRQOL in AMBASSADOR MIBC - Dr. Ronald
Chen
-Curing Early Bladder Cancer with MultiD
Approaches - Dr. Melissa Reimers
-Perioperative SHR-A2102, a novel
nectin-4-targeted antibody-drug conjugate, in
combination with adebrelimab for patients (pts) in
MIBC - Dr. Yijun Shen
-3.5 year f/u for EV-302 - Dr. Tom Powles
-Initial results from NEXUS01 ph1 LY4052031 ADC
targeting Nectin-4 - Dr. Gopa lyer
-Nectin-4 ADCs: Past, Present, Future - Dr. Andrea
Apolo
TALAPRO-3 (NCT04821622) is a Phase 3, randomised, double-blind, placebo-controlled trial of talazoparib + enzalutamide + ADT versus placebo + enzalutamide + ADT in patients with first-line metastatic castration-sensitive prostate cancer (mCSPC / mHSPC) harboring homologous recombination repair (HRR) gene alterations. The trial enrolled 599 patients globally and tested whether moving the PARP inhibitor + AR-pathway inhibitor combination — already approved in mCRPC via TALAPRO-2 — into an earlier line of therapy can extend radiographic progression-free survival in a biomarker-selected population.
In the primary analysis, the rPFS hazard ratio was 0.48 and 3-year rPFS was 76.6% vs 56%. KOLs also pointed to a 19% talazoparib discontinuation rate, two treatment-related deaths in the talazoparib arm versus none on placebo, and interim overall survival that was not statistically significant (3-yr OS 77.8% vs 71.6%, HR 0.767, P=0.0905). Physician discussion has focused on patient selection within the HRR-altered population, including how much added benefit justifies the added toxicity outside of BRCA-altered disease.
Global PI Neeraj Agarwal (Huntsman Cancer Institute, University of Utah) presented at the ASCO 2026 Bladder/Genitourinary oral session (May 30 2026, Abstract LBA5007), with simultaneous publication in NEJM. The trial sits alongside earlier mCRPC programs — TALAPRO-2 (the registrational mCRPC study for the same combination), PROpel (olaparib + abiraterone), and MAGNITUDE (niraparib + abiraterone) — and now extends the PARPi + ARPI question into the upfront, hormone-sensitive setting.
Phase 3, multicenter, randomised, double-blind, placebo-controlled trial (NCT04821622). Patients with HRR-altered 1L mCSPC randomised 1:1 to talazoparib 0.5 mg/day (or 0.35 mg/day for renal impairment) + enzalutamide 160 mg/day + ADT versus placebo + enzalutamide 160 mg/day + ADT. Stratification by high-volume vs low-volume disease and BRCA vs non-BRCA HRR alteration.
Population
N=599 patients with metastatic castration-sensitive prostate cancer and at least one HRR gene alteration per the HRR12 panel (ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, RAD51C). Eligibility required ≤3 months of ADT before randomisation and no brain metastases. Enrolment spanned US, Canada, Europe, South America, and Asia-Pacific sites.
Drug Regimen
TALZENNA (talazoparib) + XTANDI (enzalutamide) + ADT. Pfizer is the talazoparib sponsor; enzalutamide is co-developed by Pfizer and Astellas. The combination is FDA approved in HRR gene-mutated mCRPC (TALAPRO-2, June 2023) and, since October 26, 2026, in HRR gene-mutated mAPMN/S prostate cancer (TALAPRO-3).
Endpoints
Primary: radiographic progression-free survival (rPFS), investigator-assessed (RECIST v1.1; PCWG3 for bone). Key secondary (alpha-protected): overall survival. Other secondary: objective response rate, duration of soft-tissue response, PSA response, time to PSA progression, time to subsequent antineoplastic therapy, time to first symptomatic skeletal event, safety, and patient-reported outcomes. (ASCO 2026 LBA5007 trial-design slide; NEJM)
Primary Endpoint — rPFS Met (HR 0.481 (95% CI 0.357-0.647); median NOT reached)
Talazoparib + enzalutamide + ADT delivered an rPFS hazard ratio of 0.48 versus placebo + enzalutamide + ADT, with the median rPFS not reached at >3 years of follow-up. The 3-year rPFS was 76.6% (TALA + ENZA) vs 56% (placebo + ENZA), a ~20-point absolute improvement at the 3-year landmark. Benefit was reported as consistent across pre-specified subgroups, including both BRCA-altered and non-BRCA HRR populations.
rPFS met · median not reached · consistent across BRCA and non-BRCA HRR subgroups
Secondary — Time to PSA Progression (HR 0.513)
At 3 years, 78.3% of TALA + ENZA patients were free of PSA progression versus 62.7% on placebo + ENZA, hazard ratio 0.513, P<0.0001. The 95% CI for this hazard ratio was 0.370–0.712 (ASCO 2026 LBA5007; data cutoff Feb 18, 2026).
Overall Survival — Interim, Not Statistically Significant
3-year OS was 77.8% on TALA + ENZA versus 71.6% on placebo + ENZA, hazard ratio 0.767 (95% CI 0.564–1.044), P=0.0905. This interim analysis did not reach statistical significance, and OS data remain immature; OS will be formally assessed at the final analysis. Several KOLs noted the immature OS in their posts.
The most common grade ≥3 treatment-emergent adverse event was anemia: Grade ≥3 anemia in 51% of talazoparib-arm patients, with 40% requiring transfusions. Permanent discontinuation of talazoparib occurred in 19% of patients; 5% discontinued specifically because of anemia. There were 2 treatment-related deaths in the talazoparib arm and 0 in the placebo arm. Patient-reported outcomes on the EORTC QLQ-C30 "generally did not show clinically meaningful differences between the two arms, except for appetite loss." KOLs including Yüksel Ürün and @SuyogCancer weighed these toxicities against the rPFS benefit when discussing which HRR-altered patients should receive talazoparib, including in non-BRCA HRR-altered disease, where the unstratified subgroup rPFS HR was 0.57 vs 0.37 in BRCA-altered disease. Sources: Agarwal ASCO 2026 oral · OncoDaily TALAPRO-3 coverage · Fierce Pharma May 30 2026 · KOL slide OCR.
Patient-reported outcomes — ESMO 2026
Prespecified PRO analysis (EORTC QLQ-C30, EORTC QLQ-PR25, BPI-SF) presented by Arun A. Azad at ESMO 2026 (abstract 2222RO, rapid oral, Oct 23, 2026); data cutoff February 18, 2026; 474 of 599 patients (240 TALA + ENZA, 234 PBO + ENZA) had a baseline and at least one post-baseline assessment. Per the abstract, there were no clinically meaningful differences between arms (≥5-point threshold) in overall estimated mean scores for GHS/QoL, functioning and symptom scales, except appetite loss, which was worse with TALA + ENZA.
Estimated overall mean score difference, TALA + ENZA minus PBO + ENZA (95% CI): GHS/QoL −3.7 (−6.5 to −1.0); physical functioning −2.5 (−5.1 to 0.1); fatigue 3.2 (0.2 to 6.2); appetite loss 5.2 (2.5 to 8.0). Several other differences had 95% CIs excluding zero but fell below the ≥5-point threshold: constipation 4.2 (1.3 to 7.1), dyspnea 3.0 (0.1 to 5.8), nausea/vomiting 1.2 (0.2 to 2.3); together with GHS/QoL and fatigue above, these are statistically distinguishable but not clinically meaningful per the prespecified threshold. Time to definitive deterioration: GHS/QoL HR 1.16 (0.85–1.58); urinary symptoms HR 0.94 (0.61–1.44); time to deterioration in worst pain (BPI-SF) HR 0.82 (0.61–1.11) — comparable between arms. The presentation states these HRs are nominal (not alpha-controlled). (ESMO 2026 abstract 2222RO; ESMO 2026 slides; DCO 18-Feb-2026)
Data cutoff February 18, 2026 (primary rPFS analysis; interim OS). Endpoint values verbatim from Neeraj Agarwal's ASCO 2026 oral presentation (LBA5007, May 30 2026) as captured by attending KOLs (@shilpaonc, @DrChoueiri, @tompowles1, @DrYukselUrun) and reconciled with simultaneous NEJM publication and the Pfizer / Astellas joint press release. See OncoDaily TALAPRO-3 detail and Pfizer press release.
Frequently Asked Questions
TALAPRO-3 FAQ
What is the TALAPRO-3 trial?
TALAPRO-3 is a Phase 3, randomized, double-blind, placebo-controlled trial (NCT04821622) of talazoparib (Talzenna) + enzalutamide (Xtandi) + androgen deprivation therapy (ADT) versus placebo + enzalutamide + ADT in 599 patients with first-line metastatic castration-sensitive prostate cancer (mCSPC) harboring homologous recombination repair (HRR) gene alterations.
Is talazoparib + enzalutamide FDA approved based on TALAPRO-3?
Yes. On October 26, 2026, the FDA approved talazoparib (Talzenna, Pfizer) in combination with enzalutamide for adults with metastatic androgen pathway modulation-naive or -sensitive (mAPMN/S) prostate cancer with homologous recombination repair (HRR) gene mutations, as detected by an FDA-authorized test. The approval is based on TALAPRO-3.
How is the TALAPRO-3 approval different from the TALAPRO-2 approval?
They cover different disease states. In June 2023, the FDA approved talazoparib plus enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer (mCRPC), based on TALAPRO-2. The October 26, 2026 approval, based on TALAPRO-3, covers HRR gene-mutated metastatic androgen pathway modulation-naive or -sensitive (mAPMN/S) prostate cancer; TALAPRO-3 enrolled patients with metastatic castration-sensitive disease.
Which test identifies patients eligible for talazoparib + enzalutamide under the TALAPRO-3 approval?
Patients need an HRR gene mutation detected by an FDA-authorized test. The FDA notice states that FoundationOne CDx (tumor tissue) and FoundationOne Liquid CDx (blood) were previously approved as companion diagnostics for this use. TALAPRO-3 tested 12 HRR genes: ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2 and RAD51C.
Did TALAPRO-3 meet its primary endpoint?
Yes. TALAPRO-3 met its primary endpoint of radiographic progression-free survival: the rPFS hazard ratio was 0.481 (95% CI 0.357-0.647) versus placebo plus enzalutamide plus ADT, with median rPFS not reached and a 3-year rPFS of 76.6%.
What did TALAPRO-3 show for overall survival?
At the interim analysis, overall survival was not statistically significant: 3-year OS was 77.8% with talazoparib + enzalutamide versus 71.6% with placebo + enzalutamide (HR 0.767; 95% CI 0.564-1.044; p=0.0905). Longer follow-up is needed.
What did TALAPRO-3 show for patient-reported outcomes?
In the prespecified patient-reported outcome analysis presented at ESMO 2026 (abstract 2222RO; data cutoff February 18, 2026), adding talazoparib to enzalutamide generally did not produce clinically meaningful differences (≥5-point threshold) in global health status/quality of life, functioning or symptom scales versus placebo plus enzalutamide, except appetite loss, which was worse with talazoparib (estimated difference 5.2; 95% CI 2.5-8.0). Time to definitive deterioration in global health status/quality of life (HR 1.16) and urinary symptoms (HR 0.94), and time to deterioration in worst pain (HR 0.82), were comparable between arms; these hazard ratios are nominal.
Who develops talazoparib and enzalutamide?
Talazoparib (Talzenna), a PARP inhibitor, is developed by Pfizer. Enzalutamide (Xtandi), an androgen-receptor pathway inhibitor, is co-developed by Astellas Pharma and Pfizer.
Major Media & Publications
TALAPRO-3 in the News
Competitive Context — PARPi + ARPI Battle in 1L mCSPC
Pfizer's TALAPRO-3 vs J&J's AMPLITUDE (niraparib + abi / Akeega): the two head-to-head Phase 3 reads in HRR-altered 1L mCSPC tell very different stories outside of BRCA.
BRCA2: 54% rPFS improvement (driver of overall benefit per FDA exploratory analysis)
Non-BRCA: only 12% better than control
FDA approval: narrow label restricted to BRCA2
Fierce Pharma (May 30 2026): “Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer… Talzenna and Xtandi showed a robust 43% radiographic PFS improvement in the non-BRCA-mutated group, compared with 63% among BRCA-mutated patients.”
Primary publications, sponsor & institutional press releases, and major oncology media coverage around the Agarwal/Huntsman ASCO 2026 late-breaking oral presentation.
Huntsman Cancer Institute, University of Utah · TALAPRO-3 Global PI
“These data are unprecedented in their depth and have the potential to change clinical practice for first-line metastatic castration-sensitive prostate cancer with HRR alterations. TALAPRO-3 demonstrates that combining a PARP inhibitor with enzalutamide and ADT can meaningfully delay disease progression in this earlier-line setting.”
All 30 curated TALAPRO-3 physician posts from #ASCO26 and pre-conference commentary, sorted positive → neutral → cautious. Each comment is the physician's full post, verbatim. Distribution: 10 positive · 14 neutral · 6 cautious.
↗
↗
↗
↗
↗
↗
↗
↗
↗
